Xiromed intros generic Enablex
Enablex and its generics had a market value of $11.2 million for the 12-month period ended February 2021, according to IQVIA.
Patients with an overactive bladder will soon have a treatment for symptoms of urge urinary incontinence, urgency and frequency.
Xiromed is offering darifenacin ER tablets.
The product is the generic of Enablex.
“Xiromed is focused on providing quality generic products to patients in the United States and the launch of Darifenacin ER tablets is the latest example of our commitment to that goal,” said Xiromed CEO, Narasimhan Mani.
Enablex and its generics have a market value of $11.2 million, for the 12 month period ended February 2021, according to IQVIA.